Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial: Abstract No: 4501

Phase I/II trial of BAY 43-9006, carboplatin and paclitaxel demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma: Abstract No: 7507

A randomized phase I clinical and biologic study of two schedules of BAY 43-9006 in patients with myelodysplastic syndrome or acute myeloid leukemia: A National Cancer Institute of Cancer Clinical Trials Group Study: Abstract No: 6611

A phase I/II trial of BAY 43-9006 and gemcitabine in advanced solid tumors and in advanced pancreatic cancer: Abstract No: 3059

Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with refractory solid tumors: Abstract No: 3049

Novel methodology of response assessment in hepatocellular carcinoma - Assessing response by change in tumor enhancement in distinction from conventional means: Abstract No: 3107

Results of a phase I trial of BAY 43-9006 in combination with oxaliplatin in patients with refractory solid tumors: Abstract No: 3056

Pharmacodynamic study of the raf kinase inhibitor BAY 43-9006: Mechanisms of hypertension: Abstract No: 2035

BAY 43-9006 in patients with advanced melanoma: The Royal Marsden experience: Abstract No: 7506

Bayer AG published this content on 16 February 2018 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 16 February 2018 10:45:07 UTC.

Original documenthttp://www.investor.bayer.de/de/events/archiv/2004/bay-43-9006-daten-auf-dem-asco-kongress-2004/

Public permalinkhttp://www.publicnow.com/view/B607EED01D400D30DD668B79D1F4DF785B847F35